EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities

Jun Chung, Young Hwa Soung iD

Biomolecules · 2026

DOI: 10.3390/biom16050682 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Jun Chung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA. Hauptthemen laut MEDLINE: MicroRNAs, Exosomes, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carol M. Baldwin Breast Cancer Research Fund, Stony Brook Cancer Center (SBCC), Baldwin Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exosomal microRNAs (miRNAs) are key mediators of intercellular communication in the breast cancer tumor microenvironment (TME), facilitating bidirectional signaling between malignant cells and the desmoplastic stroma. This review explores current evidence on their dual roles as drivers of stromal remodeling and as circulating biomarkers of therapeutic resistance across major breast cancer subtypes, including triple-negative breast cancer (TNBC), hormone receptor-positive (ER+/PR+) disease, and HER2-amplified tumors. We outline how miR-9, miR-21, and miR-181 family members promote cancer-associated fibroblast (CAF) activation, increase extracellular matrix (ECM) stiffness, and sustain a reverse Warburg phenotype. We then detail subtype-specific resistance mechanisms: miR-181 family members suppress BCLAF1 to block doxorubicin-induced apoptosis; miR-221/222 downregulates ESR1 and p27Kip1 to confer tamoxifen resistance; miR-155 impairs homologous recombination in TNBC; and miR-1246 sustains PI3K/AKT signaling in HER2-positive disease. We also evaluate circulating exosomal miRNA panels as liquid biopsy tools for predicting chemotherapy response and tracking resistance emergence. Finally, we discuss therapeutic strategies including antagomirs, miRNA replacement therapy and engineered exosome platforms, and address key challenges such as assay standardization and regulatory hurdles, that must be overcome for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsExosomesDrug Resistance, NeoplasmBreast NeoplasmsBiomarkers, TumorHumansFemaleTumor MicroenvironmentGene Expression Regulation, NeoplasticAnimals

Stichwörter der Autor:innen

breast cancercancer-associated fibroblastschemoresistancedesmoplasiaendocrine resistanceexosomesliquid biopsymechanotransductionmiR-181 familymicroRNAtriple-negative breast cancertumor microenvironment

Substanzen

MicroRNAsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.

ORCID-Profile: Young Hwa Soung

Förderung

  • Carol M. Baldwin Breast Cancer Research Fund
  • Stony Brook Cancer Center (SBCC)
  • Baldwin Breast Cancer Research Foundation

Zitieren

APA

Chung, J., & Soung, Y. H. (2026). Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities. Biomolecules. https://doi.org/10.3390/biom16050682

Vancouver

Chung J, Soung YH. Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities. Biomolecules. 2026. doi:10.3390/biom16050682

BibTeX
@article{Chung2026,
  author = {Chung, Jun and Soung, Young Hwa},
  title = {Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16050682}
}
Kostenlos starten →